Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.

about

Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.

P2860

Q47369397-6C8EA65E-3733-4824-8C6B-27132109C0F3

P2860

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.

Item

http://www.wikidata.org/entity/Q38934988

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Population pharmacokinetics of ...... mphoblastic leukemia patients.

@en

type

Item

label

Population pharmacokinetics of ...... mphoblastic leukemia patients.

@en

prefLabel

Population pharmacokinetics of ...... mphoblastic leukemia patients.

@en

P1476

Population pharmacokinetics of ...... mphoblastic leukemia patients.

@en

P2093

Christian M Zwaan

http://www.w3.org/2001/XMLSchema#string

Cor van den Bos

http://www.w3.org/2001/XMLSchema#string

Gertjan J L Kaspers

http://www.w3.org/2001/XMLSchema#string

Inge M van der Sluis

http://www.w3.org/2001/XMLSchema#string

Marc B Bierings

http://www.w3.org/2001/XMLSchema#string

Maroeska Te Loo

http://www.w3.org/2001/XMLSchema#string

Robin Q H Kloos

http://www.w3.org/2001/XMLSchema#string

Ron A A Mathôt

http://www.w3.org/2001/XMLSchema#string

Sebastiaan D T Sassen

http://www.w3.org/2001/XMLSchema#string

Valérie de Haas

http://www.w3.org/2001/XMLSchema#string

P2860

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Tips and traps analyzing pediatric PK data.

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

A formula to estimate the approximate surface area if height and weight be known. 1916.

The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.

Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults.

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.

Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.

P304

552-561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2016.149195

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Rob Pieters

P577

2016-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28250007

http://www.w3.org/2001/XMLSchema#string

P932

5394946

http://www.w3.org/2001/XMLSchema#string

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.

about

P2860

P2860

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932